Pomalidomide

Active ingredient: Pomalidomide

In short: Pomalidomide capsules, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the la

Forms & strengths2 mg, white opaque cap and purple opaque body, imprinted with “M” on the cap and a circular band in black ink, and “2 mg” on the body in black ink 3 mg, white opaque cap and red opaque body, imprinted with “M” on the cap and a circular band in black ink, and …
LabelNovadoz Pharmaceuticals LLC
Label updatedOct 08, 2026

What is Pomalidomide used for?

Pomalidomide capsules, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

âš  Boxed warning (FDA's strongest warning)

Embryo-Fetal Toxicity

Pomalidomide is contraindicated in pregnancy. Pomalidomide is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting pomalidomide treatment.

Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping pomalidomide treatment [see Contraindications (4), Warnings and Precautions (5.1)and Use in Specific Populations (8.1, 8.3)].

Pomalidomide is only available through a restricted distribution program called PS-Pomalidomide REMS . Information about PS-Pomalidomide REMS is available at www.PS-PomalidomideREMS.com or by calling the REMS Call Center at 1-888-423-5436.

Venous and Arterial Thromboembolism

Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with pomalidomide. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors .

Pomalidomide dosage

Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating pomalidomide capsules.

The recommended dosage of pomalidomide capsules is 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression. Give pomalidomide capsules in combination with dexamethasone .

Multiple Myeloma: Dosage Modifications for Hematologic Adverse Reactions

Initiate a new cycle of pomalidomide capsules in patients with multiple myeloma (MM) when the neutrophil count is at least 500 per mcL and the platelet count is at least 50,000 per mcL.

Dosage modification for pomalidomide capsules for hematologic adverse reactions in patients with MM are summarized in Table 1.

Table 1: Dosage Modifications for Pomalidomide Capsules for Hematologic in MM

Adverse Reaction | Severity | Dosage Modification

Neutropenia | · ANC less than 500 per mcL or febrile neutropenia (fever greater than or equal to 38.5°C and ANC less than 1,000 per mcL) | · Withhold pomalidomide capsules until ANC is greater than or equal to 500 per mcL; follow CBC weekly. · Resume pomalidomide capsules dose at 1 mg less than the previous dose.*

· For each subsequent drop of ANC less than 500 per mcL | · Withhold pomalidomide capsules until ANC is greater than or equal to 500 mcL. · Resume pomalidomide capsules dose at 1 mg less than the previous dose.*

Thrombocytopenia | · Platelets less than 25,000 per mcL | · Withhold pomalidomide capsules until platelets are greater than or equal to 50,000 per mcL; follow CBC weekly. · Resume pomalidomide capsules dose at 1 mg less than the previous dose*

· For each subsequent drop of platelets less than 25,000 per mcL | · Withhold pomalidomide capsules until platelets are greater than or equal to 50,000 per mcL. · Resume pomalidomide capsules at 1 mg less than the previous dose*

* Permanently discontinue pomalidomide capsules if unable to tolerate 1 mg once daily.

ANC= absolute neutrophil count

Permanently discontinue pomalidomide capsules for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reaction .

For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion.

Avoid concomitant use of pomalidomide capsules with strong CYP1A2 inhibitors. If concomitant use of a strong CYP1A2 inhibitor is unavoidable, reduce pomalidomide capsules dose to 2 mg .

Take pomalidomide capsules after completion of dialysis procedure on hemodialysis days .

For patients with MM with severe renal impairment requiring dialysis, reduce the recommended dosage to 3 mg orally daily. …

How to take Pomalidomide — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Embryo-Fetal Toxicity

Advise patients that pomalidomide is contraindicated in pregnancy .Pomalidomide is a thalidomide analogue and may cause serious birth defects or death to a developing baby .

Advise females of reproductive potential that they must avoid pregnancy while taking pomalidomide and for at least 4 weeks after completing therapy.

Initiate pomalidomide treatment in females of reproductive potential only following a negative pregnancy test.

Advise females of reproductive potential of the importance of monthly pregnancy tests and the need to use 2 different forms of contraception, including at least 1 highly effective form, simultaneously during pomalidomide therapy, during dose interruptions, and for 4 weeks after she has completely finished taking pomalidomide. Highly effective forms of contraception other than tubal ligation include IUD and hormonal (birth control pills, injections, patch, or implants) and a partner’s vasectomy. Additional effective contraceptive methods include latex or synthetic condom, diaphragm, and cervical cap. …

Warnings & precautions

Do not take this medicine if: Pomalidomide capsules is contraindicated in females who are pregnant. Pomalidomide capsules can cause fetal harm when administered to a pregnant female . Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus.

Pomalidomide capsules is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, anaphylaxis) to pomalidomide or any of the excipients .

Pomalidomide capsules is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death . Pomalidomide capsules is only available through PS-Pomalidomide REMS .

Females of Reproductive Potential

Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning pomalidomide capsules therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy.

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with pomalidomide capsules, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of pomalidomide capsules therapy.

Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10 to 14 days and the second test within 24 hours prior to prescribing pomalidomide capsules therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles, or every 2 weeks in females with irregular menstrual cycles . …

Pomalidomide side effects

The following clinically significant adverse reactions are described in detail in other labeling sections:

Embryo-Fetal Toxicity

Venous and Arterial Thromboembolism

Increased Mortality in Patients with Multiple Myeloma When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone

Hematologic Toxicity

Hepatotoxicity

Severe Cutaneous Reactions

Dizziness and Confusional State

Neuropathy

Risk of Second Primary Malignancies

Tumor Lysis Syndrome

Hypersensitivity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Multiple Myeloma (MM)

In Trial 1, data were evaluated from 219 patients (safety population) who received treatment with pomalidomide + Low-dose Dex (112 patients) or pomalidomide alone (107 patients). Median number of treatment cycles was 5. Sixty-seven percent of patients in the study had a dose interruption of either drug due to adverse reactions. Forty-two percent of patients in the study had a dose reduction of either drug due to adverse reactions. The discontinuation rate due to adverse reactions was 11%.

In Trial 2, data were evaluated from 450 patients (safety population) who received treatment with pomalidomide + Low-dose Dex (300 patients) or High-dose Dexamethasone (High-dose Dex) (150 patients). …

Drug interactions

CYP1A2 inhibitors:

In healthy subjects, co-administration of fluvoxamine, a strong CYP1A2 inhibitor, increased Cmax and AUC of pomalidomide by 24% and 125% respectively . Increased pomalidomide exposure may increase the risk of exposure related toxicities. Avoid co-administration of strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine). If co-administration is unavoidable, reduce the pomalidomide dose .

About this medicine

Pomalidomide is a thalidomide analog. The chemical name is (RS)-4-Amino-2-(2,6-dioxo-piperidin-3-yl)-isoindoline-1,3-dione and it has the following chemical structure:

The empirical formula for pomalidomide is C13H11N3O4 and the gram molecular weight is 273.24.

Pomalidomide is a pale yellow to yellow color powder. It is soluble in dimethylsulphoxide and practically insoluble in water. Pomalidomide has a chiral carbon atom which exists as a racemic mixture of the R(+) and S(-) enantiomers.

Pomalidomide is available in 2 mg, 3 mg, and 4 mg capsules for oral administration. Each capsule contains pomalidomide as the active ingredient and the following inactive ingredients: magnesium stearate and pregelatinized starch. The 2 mg capsule shell contains gelatin, titanium dioxide, FD&C blue 1, D&C red 28, and black ink. The 3 mg capsule shell contains gelatin, titanium dioxide, FD&C blue 1, FD&C red 40, FD&C yellow 6, and black ink. The 4 mg capsule shell contains gelatin, titanium dioxide and black ink. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b8c3b7f3-7e72-47af-be23-133e7bb3db59. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate